Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy

Documenta Ophthalmologica

Volumn 117, Issue 2, 2008, Pages 93-101

  Kjellström, Ulrika ^a   Lóvestam Adrian, Monica ^a   Andréasson, Sten ^a   Ponjavic, Vesna ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Drug toxicity; Electroretinography; Epilepsy; Vigabatrin; Visual field defect

Indexed keywords

VIGABATRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; EPILEPSY; FEMALE; HUMAN; LONG TERM CARE; MALE; OSCILLATORY POTENTIAL; PERIMETRY; RETINA CONE; RETINA INJURY; RETINA ROD; VISUAL ACUITY; VISUAL FIELD; VISUAL FIELD DEFECT;

ADULT; AGED; ANTICONVULSANTS; ELECTRORETINOGRAPHY; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIMETRY; RETINA; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 49049090974     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10633-007-9108-3     Document Type: Article

References (42)

1. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie M (2003) Vigabatrin, but not gabapentin or topiramat, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44:886-892
2. Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180-181
3. Backström JT, Hinke RL, Flicker MR (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694-1695
4. Blackwell N, Hayllar J, Kelly G (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694
5. Harding GA (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694
6. Wilson EA, Brodie MJ (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1693
7. Wong ICK, Mawer GE, Sander JWAS (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694-1695
8. Kälviänen R, Nousianen I, Mänyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Reikkinen P (1999) Vigabatrin, a GABAergic antiepileptic drug, cause concentric visual field defects. Neurology 53:922-926
9. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL (1999) Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiological findings. Neurology 53:2082-2087
10. Nicolson A, Leach JP, Chadwick DW, Smith DF (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327-329
11. Ponjavic V, Andréasson S (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:63-72
12. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716-722
13. Daneshvar H, Racette MA, Coupland SG, Kertes PJ, Guberman A, Zackon D (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophtalmology 106:1792-1798
14. Nousiainen I, Mantyjarvi M, Kalviainen R (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:1916-1917
15. Wild JM, Martinez C, Reinshagen G, Harding GF (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:1784-1794
16. Krauss GL, Johnson MA, Sheth S, Miller NR (2003) A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74:339-343
17. Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M (1998) Electrophysiological evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 116:817-819
18. Graniewski-Wijnands HS, van der Torren K (2002) Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 104:189-194
19. Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B (2002) Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol 249:1066-1071
20. Newman WD, Tocher K, Acheson JF (2002) Vigabatrin associated visual field loss: A clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16:567-571
21. Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, Van Veelen C (2003) Vigabatrin: Longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 81:459-465
22. Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR (2000) Visual function loss from vigabatrin. Effect of stopping the drug Neurology 55:40-45
23. Fledelius HC (2003) Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 81:41-45
24. Krakow K, Polizzi G, Riordan-Eva P, Holder G, Macleod W, Fish D (2000) Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 9:287-290
25. Versino M, Veggiotti P (1999) Reversibility of vigabatrin induced visual-field defect. Lancet 354:486
26. Hammond EJ, Rangel RJ, Wilder BJ (1988) Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 61:16-23
27. Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, Perucca E (1989) Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 27:61-68
28. Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P (1989) Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 27:69-72
29. Mauguiere F, Chauvel P, Dewailly J, Dousse N (1997) No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy, result of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicentergroup. Epilepsia 38:301-308
30. Coupland SG, Zackon DH, Leonard BC, Ross TM (2001) Vigabatrin Effect on Inner Retinal Function. Ophthalmology 108:1493-1498
31. Westall CA, Nobile R, Morong S, Buncic RJ, Logan WJ, Panton CM (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107:299-309
32. Van der Torren K, Graniewski-Wijnands HS, Polak BCP (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104:181-188
33. Comaish IF, Gorman C, Brimlow GM, Barber C. Orr GM, Galloway NR (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: A controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104:195-2129
34. McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, Keating D, Sills GJ, Brodie MJ (2003) Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61:1690-1694
35. Scaioli V, Franceschetti S, Binelli S, Casazza M, Villani F, Granata T, Balestrini MR, Curzi S, Agazzi P, Avanzini G (2005) Serial electrophysiological studies of the visual pathway in patients treated with vigabatrin. Int Congr Ser 1278:41-44
36. Besch D, Kurtenbach A, Appfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, Schiefer U (2002) Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104:151-170
37. Marmor MF, Holder GE, Seelinger MW, Yamamoto S. International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107-114
38. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminas inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695-705
39. Frisèn L, Malmgren K (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466-473
40. Buncic RJ, Westall CA, Panton CM, Munn RJ, MacKeen LD, Logan WJ (2004) Characteristic retinal atrophy with secondary inverse optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111:1935-1942
41. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PEM (2006) Detecting vigabatrin toxicity by imaging the retinal nerve fiber layer. Invest ophthalmol vis sci 47:917-924
42. Rebolleda G, Garcia Pérez JL, Munoz Negrete FJ (2005) Vigabatrin toxicity in children (letter). Ophthalmology 112:1322-1323